Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance
Reference number: TA322
Published: 24 September 2014
Last updated: 26 June 2019

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination document

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination document

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination document
24 October 2013
(392.02 Kb 54 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 18 October 2013